ACE and cancer: This has been shown to be effective in preventing the progression of asymptomatic LV dysfunction to symptomatic HF, although in trials mainly involving ischaemic HF.27 However, the 2022 ESC Cardio-Oncology Guidelines judged that the usefulness of treatment of asymptomatic mild CTRCD with ACE-inhibitors/ARB and/or beta-blockers was not well supported by evidence or opinion (class IIb).4 In reference to the population of interest in this systematic review—adult cancer survivors at risk of late-onset HF—there are no current data on management of SBHF in this specific group.